Cache Advisors LLC Makes New $392,000 Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Cache Advisors LLC acquired a new stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,143 shares of the company's stock, valued at approximately $392,000.

Other hedge funds have also modified their holdings of the company. Arrowstreet Capital Limited Partnership increased its holdings in shares of Protagonist Therapeutics by 36.7% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 216,069 shares of the company's stock valued at $8,340,000 after purchasing an additional 58,002 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Protagonist Therapeutics by 2.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 578,409 shares of the company's stock valued at $22,327,000 after purchasing an additional 12,906 shares during the period. Barclays PLC increased its holdings in shares of Protagonist Therapeutics by 223.6% in the third quarter. Barclays PLC now owns 126,995 shares of the company's stock valued at $5,714,000 after purchasing an additional 87,755 shares during the period. Louisiana State Employees Retirement System increased its holdings in shares of Protagonist Therapeutics by 1.1% in the fourth quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company's stock valued at $1,112,000 after purchasing an additional 300 shares during the period. Finally, Pacer Advisors Inc. increased its holdings in shares of Protagonist Therapeutics by 8.2% in the fourth quarter. Pacer Advisors Inc. now owns 1,876,466 shares of the company's stock valued at $72,432,000 after purchasing an additional 142,376 shares during the period. 98.63% of the stock is owned by institutional investors and hedge funds.

Protagonist Therapeutics Price Performance

PTGX stock traded up $1.19 during mid-day trading on Thursday, reaching $46.94. 200,270 shares of the company's stock were exchanged, compared to its average volume of 996,832. The company has a market cap of $2.91 billion, a price-to-earnings ratio of 17.65 and a beta of 2.65. The stock's 50 day moving average is $45.42 and its 200 day moving average is $42.58. Protagonist Therapeutics, Inc. has a 12-month low of $27.00 and a 12-month high of $60.60.

Protagonist Therapeutics (NASDAQ:PTGX - Get Free Report) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.31. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. The company had revenue of $28.32 million for the quarter, compared to the consensus estimate of $30.44 million. On average, research analysts forecast that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on PTGX. JMP Securities reissued a "market outperform" rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a report on Friday, February 7th. HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of Protagonist Therapeutics in a research note on Monday, May 19th. JPMorgan Chase & Co. upped their target price on Protagonist Therapeutics from $53.00 to $57.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 4th. BTIG Research set a $73.00 target price on Protagonist Therapeutics in a research note on Monday, March 3rd. Finally, The Goldman Sachs Group lowered their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a "neutral" rating on the stock in a research note on Monday, February 24th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $65.44.

Insider Buying and Selling at Protagonist Therapeutics

In related news, CFO Asif Ali sold 1,756 shares of the stock in a transaction that occurred on Tuesday, April 22nd. The stock was sold at an average price of $46.00, for a total value of $80,776.00. Following the completion of the sale, the chief financial officer now owns 61,065 shares of the company's stock, valued at approximately $2,808,990. This trade represents a 2.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director William D. Waddill sold 4,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $54.25, for a total value of $217,000.00. Following the completion of the sale, the director now directly owns 13,130 shares of the company's stock, valued at approximately $712,302.50. This represents a 23.35% decrease in their position. The disclosure for this sale can be found here. Insiders sold 61,173 shares of company stock valued at $3,461,180 over the last quarter. 4.90% of the stock is currently owned by insiders.

Protagonist Therapeutics Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.